Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2019
Price : $35 *
At a glance
- Drugs Trenonacog alfa (Primary)
- Indications Haemophilia B
- Focus Therapeutic Use
- Sponsors Aptevo Therapeutics; Cangene Corporation; Emergent BioSolutions; Inspiration Biopharmaceuticals
- 20 Mar 2019 Status changed from completed to discontinued.
- 05 Jun 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Feb 2017.